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Abstract
Aims: Chronic exposure to environmental toxicants, such as
paraquat, has been suggested as a risk factor for Parkinson's
disease (PD). Although dopaminergic cell death in PD is
associated with oxidative damage, the molecular mechanisms
involved remain elusive. Glutaredoxins (GRXs) utilize the
1
reducing power of glutathione to modulate redox-dependent
signaling pathways by protein glutathionylation. We aimed to
determine the role of GRX1 and protein glutathionylation in
dopaminergic cell death. Results: In dopaminergic cells, toxicity
induced by paraquat or 6-hydroxydopamine (6-OHDA) was
inhibited by GRX1 overexpression, while its knock-down
sensitized cells to paraquat-induced cell death. Dopaminergic
cell death was paralleled by protein deglutathionylation, and this
was reversed by GRX1. Mass spectrometry analysis of
immunoprecipitated glutathionylated proteins identified the actin
binding flightless-1 homolog protein (FLI-I) and the RalBP1-
associated Eps domain-containing protein 2 (REPS2/POB1) as
targets of glutathionylation in dopaminergic cells. Paraquat
induced the degradation of FLI-I and REPS2 proteins, which
corresponded with the activation of caspase 3 and cell death
progression. GRX1 overexpression reduced both the
degradation and deglutathionylation of FLI-I and REPS2, while
stable overexpression of REPS2 reduced paraquat toxicity. A
decrease in glutathionylated proteins and REPS2 levels was
also observed in the substantia nigra of mice treated with
paraquat. Innovation: We have identified novel protein targets
of glutathionylation in dopaminergic cells and demonstrated the
protective role of GRX1-mediated protein glutathionylation
against paraquat-induced toxicity. Conclusions: These results
demonstrate a protective role for GRX1 and increased protein
glutathionylation in dopaminergic cell death induced by paraquat,
and identify a novel protective role for REPS2. Antioxid. Redox
Signal. 17, 1676–1693.
Introduction
PARKINSON'S DISEASE (PD) is characterized by the selective loss of
dopaminergic neurons of the substantia nigra pars compacta (SNpc) (71).
Previous studies have indicated that exposure to environmental toxins such
2
as herbicides and pesticides increase the risk of developing PD by
increasing oxidative stress and mitochondrial dysfunction (24, 25, 28, 80).
Although dopaminergic cell death is a cardinal feature of PD, the
mechanisms and pathways involved remain unclear. Current evidence
supports a role for mitochondrial dysfunction, oxidative stress, and
abnormal protein accumulation as early triggers of neuronal death in PD
(50, 62, 92). Oxidative damage to lipids, proteins, and DNA, as well as a
decrease in the levels of the low molecular thiol antioxidant glutathione
(GSH), have been detected in samples from individuals with PD (1, 2, 22,
42, 60). Oxidative stress in PD is linked primarily with mitochondrial
dysfunction as demonstrated by reports showing decreased activity of the
mitochondrial electron transport chain in the substantia nigra of patients
with PD (35, 70, 73).
An increase in protein oxidation has been reported in brains from PD
patients as evidenced by the accumulation of oxidative and nitrosative
protein modifications (1, 21). An important cellular target or sensor of
reactive species is the thiol group (SH) of the amino acid cysteine. Redox-
sensitive cysteines in proteins undergo oxidative modifications in response
to reactive oxygen (ROS) or nitrogen species, thereby modulating protein
function, activity, and/or localization. Oxidation and reduction of cellular
thiols are thought to be major mechanisms by which oxidative stress is
integrated into cellular signal transduction pathways (61, 88). Protein
glutathionylation is defined as the reversible formation of a mixed-disulfide
between GSH and protein thiols involved in the redox-regulation of protein
function (19, 55). Previous studies have demonstrated the occurrence of
protein glutathionylation/deglutathionylation in dopaminergic cells.
Mitochondrial protein deglutathionylation has been reported in response to
oxidative stress in dopaminergic cells (56). In contrast, increased
3
glutathionylation of the mitochondrial NADP(+)-dependent isocitrate
dehydrogenase (IDPm) was reported in the MPTP mouse PD model (47).
However, the role of protein glutathionylation in dopaminergic cell death in
other experimental PD models, particularly those associated with
environmental toxicants, has not been studied in detail.
Innovation
Dopaminergic cell death in PD is associated with increased oxidative
damage. However, the mechanisms by which redox signaling regulates
cell death progression are still unclear. We demonstrated, for the first
time, the protective role of the thiol oxidoreductase GRX1 against
dopaminergic cell death induced by the environmental pesticide
paraquat, and the dopaminergic toxin 6-OHDA. We also demonstrated
that the protective effect of GRX1 is ascribed to the regulation of
glutathionylation/deglutathionylation of cellular protein targets.
Additionally, we identified novel molecular targets for protein
glutathionylation that include the actin-binding protein FLI-I and the
RalBP1-associated Eps domain-containing protein REPS2/POB1; and
for the case of REPS2, we demonstrated its protective effect against
dopaminergic cell death induced by paraquat. Finally, we found that
overall PSSG and REPS2 levels were decreased in the substantia nigra
of mice treated with paraquat.
In this study, we demonstrated a protective role of GRX1 and protein
glutathionylation in dopaminergic cell death induced by paraquat and 6-
OHDA. More importantly, we identified the actin binding flightless-1
homolog protein (FLI-I) and the RalBP1-associated Eps domain-containing
4
protein 2 (REPS2/POB1) as novel targets of protein glutathionylation in
dopaminergic cells. Paraquat-induced dopaminergic cell death was
paralleled by degradation of FLI-I and REPS2 protein, and overexpression
of REPS2 significantly reduced dopaminergic cell death induced by
paraquat. A decrease in glutathionylated residues and REPS2 protein levels
was also observed in the substantia nigra of mice treated with paraquat.
These results describe a protective role for GRX1-mediated protein
glutathionylation in dopaminergic cell death associated with PD and
demonstrate a novel protective role for REPS2.
Results
GRX1 protects against experimental PD
Recent studies have demonstrated that the exposure to environmental toxins,
such as paraquat, is strongly associated to an elevated risk of developing PD
progression (5, 14, 80), which might be mediated by increased oxidative
stress and mitochondria dysfunction (24, 27, 74). The oxidoreductase GRX1
has been shown to exert a protective effect against dopamine and MPTP
toxicity in neuronal cells (16, 17, 46). However, the role of GRX1 in other
experimental models of PD has not been studied in detail. Recent studies
have demonstrated that GRX1 is expressed at lower levels in the substantia
nigra and striatum compared to the hippocampus and cerebral cortex (3, 7).
Human dopaminergic SK-N-SH cells express very low levels of GRX1,
which, as shown here, can be increased by stable expression or adenoviral
gene delivery (Figs. 1A and 2A). Stable expression of GRX1 in human
dopaminergic cells (Fig. 1A) protects against paraquat induced toxicity (Fig.
1B–1C). More specifically, we observed that GRX1 significantly prevented
the loss of mitochondrial activity (Fig. 1B) and cell viability (Fig. 1C) upon
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paraquat exposure. To determine if the protective effect of GRX1
overexpression was restricted to paraquat-induced dopaminergic death, we
evaluated its role in cell death induced by 6-OHDA, another widely used
neurotoxin for experimental PD. As shown in Figure 1D, GRX1
overexpression significantly reduced 6-OHDA toxicity. These results
highlight the protective role of GRX1 against distinct experimental models
of PD.
View larger version
FIG. 1. Stable overexpression of GRX1 protects against
dopaminergic cell death induced by paraquat and 6-OHDA.
Human dopaminergic SK-N-SH cells were stably transfected with
empty pCR3.1 vector and pCR3.1 vector encoding human GRX1
(A). In B–D, the effect of GRX1 overexpression against cell death
induced by a 48 h treatment with paraquat (0.5 mM in C) or 6-OHDA
(50 μM) (D) was analyzed by determination of mitochondrial activity (B) and cell
viability (C and D). Mitochondrial activity (B) was assessed by measuring the
conversion of the tetrazolium salt, MTT. Loss of cell viability or plasma membrane
integrity is reflected by the increase in the number of cells with increased PI
fluorescence (plots and bar graphs in C and D). Data in bar graphs represent % of
viable cells from paraquat (C) and 6-OHDA (D) treated cells and are means±SEM of
four independent experiments. *p<0.05, significant difference between GRX1 and
pCR3.1 values. Contour plots and Western blots are representative of 2–4
independent experiments. Numbers in A represent the densitometry analysis with
respect to SK-N-SH cells normalized to β-actin.
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View larger version
FIG. 2. Adenovirus-mediated overexpression of GRX1 and
shRNA knock-down regulate dopaminergic cell death induced
by paraquat. Overexpression of GRX1 by recombinant adenovirus
Ad5CMV-GRX1 (1.5 MOI) and GRX1 knock-down with shRNA
lentiviral particles were determined by Western blot (A). The effect of
GRX1 overexpression (C and D) and knock-down (B) on the loss of
mitochondrial activity (B and D) and cell death (C) induced by
paraquat was determined as in Figure 1. In E, the effect of paraquat
(48 h treatment) on the overexpression of GRX1 induced by Ad5CMV-GRX1 (1.5 MOI)
was evaluated. Cleavage of α-fodrin (apoptotic marker) and accumulation of LC3-II
(autophagy marker) induced by paraquat were also determined by Western blot in
whole cell lysates (F). Control adenovirus contained only the cytomegalovirus promoter
(AdEmpty) and/or the green fluorescent protein gene as a reporter (AdGFP). Data in
graphs represent means±SEM of four independent experiments. *p<0.05, shRNA4
and 8 vs Scramble (C), or GRX1 vs. Empty values (D). Plots in (C) represent 0.5 mM
PQ treatments. Contour plots and Western blots are representative of 3–4
independent experiments. Numbers in blots (italics) represent the densitometry
analyses with respect to Scramble (A), Ad-GRX1 (E), and Ad-Empty samples (F)
normalized to β-actin or GAPDH.
To further corroborate the protective role of GRX1 against experimental PD,
we used both lentivirus-mediated delivery of shRNA against GRX1 and
adenovirus-induced GRX1 overexpression. GRX1 shRNAs (shRNA-4 and
shRNA-8) stably expressed in SK-N-SH cells, were able to decrease both
basal levels of GRX1 and adenovirus-mediated GRX1 overexpression (Fig.
2A). Knock-down of GRX1 increased paraquat-induced dopaminergic cell
death as determined by decreased mitochondrial activity (Fig. 2B).
Conversely, overexpression of GRX1 significantly prevented both the
decrease in cell viability (Fig. 2C) and the loss of mitochondrial activity
upon paraquat exposure (Fig. 2D). Paraquat induced a dose-dependent
decrease in the levels of overexpressed GRX1, which explains why a 9-fold
increase in GRX1 levels (Fig. 2A) does not completely prevent PQ toxicity
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(Fig. 2C).
Paraquat-induced dopaminergic cell death has been associated with the
activation of apoptosis and alterations in autophagic pathways (26, 30, 58).
Therefore, we wanted to identify the role of GRX1 in regulating distinct
signaling pathways. Figure 2F demonstrates that overexpression of GRX1
reduces the cleavage of the selective caspase 3 substrate α-fodrin (15, 41,
87), a reliable marker of apoptosis highly and predominantly expressed in
neuronal cells (31, 57). GRX1 also reduced the accumulation of LC3-II as a
marker of autophagosome accumulation (Fig. 2F), demonstrating that GRX1
reduces the activation of both apoptotic and autophagic signaling cascades.
Paraquat induces alterations in cellular levels of glutathionylated
protein residues
Oxidative stress is associated with increased protein oxidation and
alterations in protein glutathionylation. Protein S-glutathionylation refers to
the formation of a protein mixed disulfide between the thiol of GSH and the
cysteine moiety of a protein (thiol exchange reaction). To examine
alterations in protein glutathionylated residues (PSSG) induced by paraquat,
whole cell lysates of human dopaminergic cells with or without paraquat
treatment were isolated under nonreducing conditions. Figure 3A shows that
paraquat induced alterations in overall levels of glutathionylated proteins.
Unique protein bands ranging from 37–150 kD were identified, whose signal
was reversed when analyzed under reducing conditions (Fig. 3B). In some
cases, low concentrations of paraquat induced a slight increase in protein
glutathionylation for specific protein bands (broken line rectangle), but
higher concentrations were associated with a decrease in PSSG (Fig. 3A and
densitometry analysis).
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View larger version
FIG. 3. Paraquat-induced alterations in glutathionylated
proteins. Whole cell lysates of cells treated with or without paraquat
for 48 h were isolated and analyzed under reducing (-NEM/+DTT)
and nonreducing (+NEM/-DTT) conditions. In A and B, protein
glutathionylation was assessed using anti-PSSG antibody in
samples isolated in the presence or absence of >30 mM NEM. In C,
overexpression of GRX1 was induced via adenoviral transduction
(1.5 MOI) as described in Figure 2. C represents a composite of two
independent Western blot with their corresponding loading controls. In D, protein
glutathionylation was assessed as previously described in cells labeled with BioGEE
(250 μM) 1 h prior to experimental treatments, and glutathionylated proteins were
visualized using streptavidin-HRP conjugate. Blots were probed with β-actin to
determine equal loading. Blots are representative of at least 3 independent
experiments. Numbers in blots (italics) represent the densitometry analyses with
respect to control (A, table), and Ad-Empty samples (C and D) normalized to β-actin.
Interestingly, overexpression of GRX1 induced distinct effects on
glutathionylated proteins (Fig. 3C). In response to paraquat, a decrease in
protein glutathionylation was observed in protein bands around 100–150 kD.
GRX1 overexpression increased glutathionylation of these protein bands and
this was further increased upon paraquat treatment (Fig. 3C, upper panels a
and b). In contrast, paraquat was shown to enhance PSSG of a protein band
between 37 and 50 kD (Fig. 3C, lower panel). The glutathionylation of this
same protein band was increased by GRX1 itself, but in the presence of
paraquat, protein glutathionylation was inhibited. Although it is not possible
to determine whether changes in every PSSG band signal are ascribed to
single or multiple proteins, these results suggested that alterations in PSSG
in response to paraquat and GRX1 overexpression vary according to the
molecular identity of the target.
GRX1 activity is usually associated with protein deglutathionylation. To
9
further confirm the observation that protein glutathionylation was increased
by GRX1 overexpression, we used biotinylated GSH (BioGEE) to label the
intracellular GSH pool. Figure 3D (left panel) shows that overexpression of
GRX1 also increased the levels of glutathionylated proteins when labeled
with BioGEE, corroborating our observation that increased GRX1 can
stimulate protein glutathionylation. Interestingly, most of the pool of
glutathionylated proteins labeled with BioGEE showed an increase in PSSG
in response to paraquat treatment, which might imply that labeling protocols
for PSSG using either anti-PSSG or BioGEE could actually detect different
pools of glutathionylated proteins. It is important to note that modification
of the glutathionyl moiety by the bulky biotin molecule is likely to interfere
with both enzymatically catalyzed glutathionylation and
deglutathionylationation by GRXs (reviewed by Mieyal et al. in Ref. 54).
Reducing conditions (+DTT) only partially reversed BioGEE labeling of
PSSG residues (Fig. 3D, right panel). Previous studies have shown that some
biotin–GSH moieties of glutathionylated proteins are largely resistant to
DTT reversal (38).
Paraquat induces the downregulation of flightless-1 homolog protein
and the RalBP1-associated Eps domain-containing protein 2
Previous studies have demonstrated the occurrence of protein
glutathionylation/deglutathionylation in dopaminergic cells in response to
oxidative conditions (52). Glutathionylation of the mitochondrial IDPm was
recently reported in the MPTP mouse PD model (47). However, to our
knowledge, no other molecular targets have been identified since then in PD
models associated with environmental toxicants. We proceeded to identify
novel molecular targets for protein glutathionylation/deglutathionylation in
dopaminergic cells using mass spectrometry. Paraquat is known to induce
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oxidative stress in both mitochondrial and cytosolic compartments (10, 13,
64). We utilized whole cell lysates of untreated dopaminergic cells to
immunoprecipitate glutathionylated proteins, which were subsequently
analyzed by mass spectrometry in order to identify potential targets for
glutathionylation/deglutathionylation upon paraquat exposure. Some of the
peptides identified by mass spectrometry analysis corresponded to the actin
binding flightless-1 homolog protein (FLI-I, peptide sequence:
ACSAIHAVNLR) and the RalBP1-associated Eps domain-containing
protein 2 (REPS2/POB1, peptide sequence:
SAGSAEQVAPAAAQGGSSRTNCIGKPIGTTSSGHCVV), which have not
been previously identified to be subject to oxidative post-translational
modification (Fig. 4A, Supplementary Fig. S1; supplementary data are
available online at www.liebertonline.com/ars). Supplementary Table 1 lists
all the proteins identified in PSSG immunoprecipitates from SK-N-SH cells.
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View larger version
FIG. 4. Paraquat toxicity is associated with downregulation
of FLI-I and REPS2. (A) Glutathionylated proteins
immunoprecipitated with anti-PSSG antibody were processed for
mass spectrometry. Samples were digested with trypsin and
peptides were subjected to LC/MS/MS analysis using reverse phase
chromatography mass spectrometry. Two of the acquired spectrum of peptides
identified by mass spectrometry analysis corresponded to FLI-I (ACSAIHAVNLR) and
REPS2 SAGSAEQVAPAAAQGGSSRTNCIGKPIGTTSSGHCVV), identified using a
human data base (IPI-Human, NCBI). (See Supplementary Fig. S1 for a magnification
of the MS spectra). Alterations in the levels of FLI-I, REPS2 and cleaved caspase 3
induced by paraquat were assessed in wild-type (B) and stable SK-N-SH
overexpressing Myc-His REPS2 (D). In (C) and (D), REPS2 protein levels were
visualized in stable Myc-His REPS2 overexpressing clones (clone 2 was used in D)
using anti-myc-tag (upper panel) or anti-REPS2 (K-18) (lower panel) antibody. a–c
labels in C and D (including the table) represent possible isoforms or degradation
products of REPS2. Blots were reprobed with β-actin to corroborate equal loading
and are representative of at least 3 independent experiments. Table corresponds to
the densitometry analysis of protein bands in D. Numbers (italics) in (B) and (D)
represent the densitometry analyses with respect to control samples (D, table)
normalized to β-actin.
We next determined the effect of paraquat exposure on protein levels of
both FLI-I and REPS2. Paraquat-induced dopaminergic cell death was
paralleled by a significant decrease in FLI-I protein levels (Fig. 4B), which
corresponded with the activation of apoptosis as shown by the increased
cleavage/activation of executioner caspase 3 (Fig. 4B). At high
concentrations of PQ and high degree of cell death, no cleaved caspase 3 is
detected. This is explained by the well-known observation that active
caspase 3 is rapidly degraded by a mechanism that is dependent on the
catalytic activity of the active enzyme (81). The effect of paraquat was also
determined in stable cells overexpressing REPS2. Four isoforms of REPS2
have been identified: two short isoforms comprising 521 or 522 amino acid
residues (58 kD) and two long ones of 659 or 660 residues (78 kD) (6).
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Stable overexpression of REPS2 in dopaminergic cells lead to the detection
of a 78 kD and 58 kD isoforms (Fig. 4C and 4D). Three other bands at ∼50 
kD (a), ∼32 kD (b), and ∼26 kD (c), which could be distinct isoforms or
degradation products, were also detected (Fig. 4C and 4D). Detection of
basal levels of REPS2 protein was not possible as the commercially
available antibody used (K-18, Santa Cruz) did not seem to be specific
enough for WB. This was demonstrated by the observation that this antibody
was not able to detect myc-tagged REPS2 in our stable cells (Fig. 4C, lower
panel), which is recognized by anti-myc-Tag antibody (Fig. 4C, upper
panel). Similar to FLI-I, paraquat induced a dose-dependent decrease in the
78 kD isoform (Fig. 4D, broken line rectangle), which paralleled an increase
in the other protein bands (Fig. 4D, dotted rectangles and densitometry
analysis), suggesting that these might be byproducts of REPS2 degradation.
REPS2 degradation was also paralleled by the cleavage/activation of
caspase 3 (Fig. 4D, lower panel).
We next determined the effect of GRX1 on protein glutathionylation and
expression levels of FLI-I and REPS2. Overexpression of GRX1 was shown
to significantly reduce paraquat-induced FLI-I degradation (Fig. 5A, broken
line rectangles). Similarly, GRX1 overexpression decreased the degradation
of REPS2 (78 kD and 58 kD bands) (Fig. 5B). FLI-I was first
immunoprecipitated under nonreducing conditions to determine the
alterations in PSSG upon GRX1 overexpression and paraquat treatment.
Overexpression of GRX1 was associated with an increase in
glutathionylation of FLI-I in the presence of paraquat (Fig. 5C). Reverse-
immunoprecipitation with anti-PSSG antibody and blot analysis with anti-
FLI-I antibody corroborated the observation that GRX1 overexpression
prevented the decrease in glutathionylated FLI-I by paraquat. These results
suggest that GRX-1-mediated protein glutathionylation reduces the
13
degradation of cellular substrates upon oxidative stress induced by paraquat.
View larger version
FIG. 5. GRX1 regulates protein expression levels and
glutathionylation of FLI-I and REPS2. In (A) and (B),
overexpression of GRX1 (Ad-GRX1) reduced paraquat-induced FLI-I
and REPS2 downregulation (broken line rectangles). SK-N-SH (A
and C) and cells stably expressing Myc/His REPS2 (B and D) were
infected with Ad-Empty or Ad-GRX1 (1.5 MOI) for 24 h and subsequently treated with
paraquat (0.2 mM in A, C upper panel, and D) for 48 h. Samples were collected under
nonreducing conditions (+NEM/-DTT). In C (upper panel) and D, FLI-I and REPS2
were immunoprecipitated with anti-FLI-I or anti-MycTag antibodies respectively, and
then, PSSG were visualized using anti-PSSG antibody. Blot in (C, upper panel) was
reprobed with anti-FLI-I to corroborate equal levels of immunoprecipitated proteins. In
(C, lower panel), glutathionylated proteins were immunoprecipiated with anti-PSSG
antibody and FLI-I levels were visualized using the corresponding antibody. As
controls, samples were pre-cleared with Dynabeads coupled with normal mouse IgG.
Normal mouse IgG did not pull down FLI-I. Blots are representative of at least 3
independent experiments. Numbers in blots (italics) represent the densitometry
analyses with respect to Ad-Empty samples [0.15 MOI, upper numbers; and 1.5 MOI
lower numbers in (A)], normalized to the corresponding loading/input control.
Myc-tagged REPS2 was immunoprecipitated and alterations in PSSG
induced by paraquat treatment or GRX1 overexpression were also analyzed.
Under nonreducing conditions, the anti-Myc-tag recognized a band >100 
kD, which might be either REPS2 complexes or eluted Ig heavy and light
chains. Two bands at >80 kD and 58 kD that seem to correspond to the 78 
kD and 58 kD isoform were detected using the anti-PSSG antibody,
suggesting basal glutathionylation of these isoforms (Fig. 5D, broken lines).
Overexpression of GRX1 increased the glutathionylation of the >80 kD
protein, while it decreased the PSSG levels in the 58 kD band. Exposure of
the GRX1 overexpressing cells to paraquat deglutathionylated the >80 kD
isoform, which correlated with an increase in the glutathionylation levels of
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the 58 kD isoform. Interestingly, paraquat treatment of GRX1
overexpressing cells also induced an increase in the glutathionylation of the
b and c protein bands described in Figure 4 (Fig. 5D, lower panel
overexposed). It is important to mention that under nonreducing conditions
the migration pattern of the 78 kD and 58 kD isoforms of REPS2 and of their
possible degradation products might not correlate with the MW of the
protein markers used to identify them. This is because the experimental
samples were analyzed under nonreducing conditions (-DTT+NEM), which
affect their migration pattern, while recombinant proteins in the protein
markers are already reduced (+DTT in the manufacturer's loading buffer).
REPS2 overexpression protects against dopaminergic cell death
induced by paraquat
Oxidative stress has been clearly linked to dopaminergic cell death in PD.
However, the exact molecular mechanisms by which oxidative stress and
redox signaling trigger dopaminergic cell death are unknown. Our results
indicate a possible link between degradation of FLI-I and REPS2 proteins
and dopaminergic cell death induced by paraquat. Very little is known
regarding the role of FLI-I and REPS2 in cellular survival or death. We
observed that paraquat treatment induced a decrease in these proteins and
this was associated with an increase in the activation of cell death pathways,
particularly, the activation of caspases. Thus, we wanted to assess if
overexpression of these proteins would modulate dopaminergic cell death
induced by paraquat. In two distinct clones of cells stably overexpressing
REPS2, paraquat-induced cell death was significantly reduced (Fig. 6A–6B).
Figure 6A demonstrates that dopaminergic cell death induced by paraquat,
which is observed as an increase in the permeability of the plasma
membrane (detected by the uptake of PI) and cell shrinkage (a common
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hallmark of apoptotic cell death), was significantly prevented by REPS2
overexpression when compared with cells containing the empty vector
(pcDNA). REPS2 overexpression also reduced the cleavage/activation of
caspase 3, suggesting a role for REPS2 in regulating apoptotic signaling
cascades (Fig. 6B). In contrast to REPS2, overexpression of FLI-I (Fig. 6C–
6D) had no effect on paraquat-induced cell death. These results demonstrate
for the first time a protective effect of REPS2 against dopaminergic cell
death induced by paraquat. Dopaminergic cell death induced by the
parkinsonian drugs 6-OHDA (50 μM) or the complex I inhibitors rotenone
(4 μM) or MPP+ (1-methyl-4-phenylpyridinium, 2.5 mM), also used as
experimental paradigms of PD, was unaltered by either REPS2 or FLI-I
overexpression (data not shown). These are not surprising results as it has
been reported that dopaminergic cell death induced by either paraquat,
rotenone, MPP+ or 6-OHDA involves the activation of distinct redox
signaling cascades (11, 32, 53, 64, 82). These results also demonstrate that
the protective role of REPS2 is specific for paraquat-induced cell death, and
that REPS2 overexpression does not impair the overall sensitivity of cells to
cell death stimuli.
16
View larger version
FIG. 6. Paraquat-induced dopaminergic cell death is
significantly reduced by REPS2/POB1 overexpression. (A)
SK-N-SH cells overexpressing empty pcDNA3.1 or Myc-His
REPS2 were treated with paraquat for 48 h. Cell death was determined by the loss of
plasma membrane integrity (PI uptake) and cell shrinkage as a marker of apoptosis.
% of dead cells in A (bar graph) reflects the number of cells with increased PI
fluorescence using two distinct clones overexpressing Myc-His REPS2 (See Fig. 4C).
In B, paraquat-induced cleavage/activation of caspase 3 in both pcDNA3.1 and
REPS2 overexpressing cells was evaluated as explained in Figure 2. In C and D, cells
were transiently transfected with Myc-tagged FLI-I for 24 h prior paraquat treatment.
Expression levels of FLI-I were corroborated by Western blot (C) and the effect of FLI-I
overexpression on paraquat-induced dopaminergic cell death was determined as
explained in A. Data in A (bar graphs) and D are means±SEM of four independent
experiments. *p<0.05, significant difference between the corresponding REPS2 and
pcDNA3.1 values. Contour plots and western blots are representative of 3–4
independent experiments. Numbers in B (italics) represent the densitometry analyses
of cleaved caspase 3 with respect to pcDNA normalized to β-actin.
To corroborate these results in vivo, C57BL/6 mice were administered two
intraperitoneal injections of 10 mg/kg paraquat or PBS every week for 3
consecutive weeks. Animals were analyzed 1 week after the last injection
and histological sections of the substantia nigra were stained with anti-TH
(tyrosine hydroxylase), anti-PSSG, or anti-REPS2 antibody. Figure 7
demonstrates that paraquat-induced toxicity is associated with a decrease in
PSSG (Fig. 7A) and REPS2 (Fig. 7B) levels in the substantia nigra in vivo.
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FIG. 7. Alterations in PSSG and REPS2 in the substantia
nigra of mice treated with paraquat. C57BL/6 mice (8–10 weeks
old) were administered two intraperitoneal injections of 10 mg/kg PQ
or PBS every week for 3 consecutive weeks. Animals were analyzed
1 week after the last injection and coronal sections of the substantia nigra were
stained with anti-TH (A and B) and anti-PSSG (A) or anti-REPS2 (B) antibody.
Sections were incubated in secondary Alexa 488-anti-rabbit (TH) and Alexa 633-anti-
mouse (PSSG and REPS2). Sections were mounted with VectaShield and images
were collected on a LSM 5 Exciter confocal scanning fluorescent microscope (20 ×)
and Zen 2008 software (Carl Zeiss). Fluorescence intensity analysis was performed
using ImageJ (NIH) software. Corrected total cell fluorescence (CTCF) was obtained
and expressed as Arbitrary Fluorescence Intensity Units (A.U.).
Discussion
Dopaminergic degeneration in PD is associated with increased oxidative
damage. However, the mechanisms by which oxidative stress and redox
signaling regulate cell death are unclear. In this study, we demonstrated the
protective role of the thiol oxidoreductase GRX1 against the dopaminergic
cell death in experimental PD. More specifically, GRX1 was able to
significantly reduce dopaminergic cell death induced by paraquat, an
environmental pesticide linked by epidemiological studies to an increased
risk in PD; and 6-OHDA, a dopaminergic toxin that triggers oxidative
damage. Furthermore, we demonstrated that the protective effect of GRX1
is ascribed to an increased glutathionylation that seems to regulate protein
degradation during cell death. Finally, we have also identified novel
molecular targets for protein glutathionylation, including FLI-I and REPS2;
and, for the case of REPS2, we demonstrated its protective effect against
dopaminergic cell death induced by paraquat. These results were
corroborated in vivo as shown by the decrease in PSSG and REPS2 levels in
the substantia nigra of mice treated with paraquat.
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Although dopaminergic cell death is a cardinal feature of PD, the
mechanisms and pathways involved remain unclear, mainly because in the
majority of cases the cause of PD is unknown. A fraction of PD occurrence
is related to mutations in genes such as α-synuclein, DJ-1, PINK1, LRRK2,
and parkin. However, over 90% of PD occurs most commonly in a sporadic
(idiopathic) form without a clearly defined genetic basis, and only a vaguely
delineated pathogenesis likely linked to environmental causes. Thus, it is
thought that PD arises from the convergence of genetic susceptibility,
environmental exposures, and aging, which is the major factor increasing
PD risk (37, 84). However, the etiology of PD has yet to be clearly
established. Given recent reports strengthening the association between
pesticide exposure and increased risk in PD, we decided to study the role of
protein glutathionylation and the protective effect of GRX1 in dopaminergic
cell death induced by exposure to paraquat, an environmental pesticide
whose occupational exposure is linked to PD (23, 80).
To understand the redox signaling events that regulate dopaminergic cell
death in experimental PD, we need to identify the molecular targets of
oxidative modification. By regulating protein structure and activity,
oxidative post-translational modifications regulate a variety of
physiological processes. One of the primary targets of oxidation within a
protein is the amino acid cysteine, whose thiol side chain is highly sensitive
to different types of oxidizing agents. Reversible thiol modification is a
major component of the modulation of cell-signaling pathways by ROS.
Cysteine oxidation by ROS leads to the formation of the reactive (highly
unstable) intermediate cysteine sulfenic acid (PSOH), which, if not reduced,
can either participate in disulfide bond formation with GSH (protein
glutathionylation) (Fig. 8E) or lead to irreversible oxidation (sulfonic acid)
(Fig. 8C and 8G). Protein glutathionylation has also been demonstrated to be
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mediated by additional mechanisms (55). For example, PSSG formation
might occur by thiol exchange reactions between protein cysteines and
glutathione disulfide (GSSG) (Fig. 8A), but this mechanism requires an
unusually high redox potential only reported for a limited number of protein
targets (55). Protein cysteines and GSH can undergo nitrosylation forming
protein-SNO and (S-)nitrosoglutathione (GSNO) and biochemical studies
demonstrate the potential of GSNO to promote protein S-glutathionylation
(55). Paraquat generates oxidative stress by an increased accumulation of
reactive species such as superoxide anion (•O2-) and hydrogen peroxide
(H2O2), which parallel a decrease in cellular GSH levels and increased
generation of GSSG (44). Interestingly, we observed distinct effects of
paraquat exposure on PSSG levels. In some cases, paraquat toxicity was
paralleled by a decrease in PSSG residues (Fig. 3A and 3C). This might be
associated with: 1) a depletion of intracellular GSH preventing its reaction
with PSOH residues and the formation of PSSG residues (Fig. 8C–8E); and
2) the hyperoxidation of PSOH residues (Fig. 8G). In some other protein
bands, paraquat induced an increase in PSSG levels (Fig. 3A and C), which
might be mediated by the increased accumulation of GSSG and its reaction
with protein targets with high redox potential (Fig. 8A). These results
demonstrate the occurrence of distinct glutathionylation/deglutathionylation
mechanisms induced by paraquat that could be related to distinct protein
localization, surrounding redox environment (availability of GSH or GSSG),
and the nature of the reactive species involved.
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FIG. 8. Proposed mechanism by which paraquat-induced
oxidative stress and GRX1 might regulate protein
glutathionylation and deglutathionylation distinctively. Protein
glutathionylation has been demonstrated to occur by a variety of
mechanisms, reviewed in (55, 88). (A) PSSG formation might occur
by thiol exchange reactions between protein cysteines and GSSG,
but this mechanism requires unusually high redox potential. Interestingly, under
oxidizing conditions (low GSH/GSSG ratio) GRX1 can use GSSG to promote PSSG
formation. Paraquat-induced↑RS might enhance GRX1-mediated glutathionylation by
increasing the GSSG pool (dotted line). (B) Under reducing conditions, GRX1 utilizes
the reducing power of GSH to catalyze protein deglutathionylation. Paraquat-induced
reactive species (↑ RS) formation might prevent GRX1-mediated deglutathionylation
by depletion of intracellular GSH content (broken lines). On the other hand, two (H2O2,
•ONOO-) or one-electron (•O2-) cysteine oxidation by RS leads to the formation of
reactive intermediates including cysteine sulfenic acids (PSOH) (C) and protein thiyl
radicals (PS•) (D), respectively, which can participate in disulfide bond formation with
GSH leading to PSSG formation (E). In addition, GS• generation by oxidative stress
has been shown to lead to PSSG formation catalyzed by GRXs (not depicted here).
This is another potential mechanism by which GRX1 overexpression might increase
protein glutathionylation upon paraquat exposure. Paraquat-induced RS formation and
GSH depletion mediated by increased activation of glutathione peroxidase (GPX)
(broken lines) might enhance cysteine oxidation and also prevent/reverse cysteine
glutathionylation leading to their irreversible oxidation (G). Thus,
glutathionylation/deglutathionylation depends on the spacial localization of the targeted
protein, surrounding redox environment, the nature of the RS involved and expression
levels of GRXs (F).
Protein glutathionylation linkages are removed by changes in the
intracellular GSH/GSSG balance and/or the activities of GRX enzymes.
GRXs are oxidoreductases that under reducing conditions utilize the
reducing power of GSH to catalyze protein deglutathionylation (reduction of
mixed disulfides) (Fig. 8B) (55). Interestingly, formation of PSSG has also
been observed as a result of thiyl radical formation by reactive species
(protein thiyl [PS•] and glutathionyl [GS•] radicals), which can be
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catalyzed by GRXs (29, 63, 78). This suggests that protein
glutathionylation/deglutathionylation catalyzed by GRX1 depends upon the
redox environment of the cell, with the potential to act as a
glutathionylating enzyme under oxidative stress, and as a deglutathionylase
under reducing conditions (high GSH availability) or when the oxidative
stress subsides (9, 55). Previous studies have demonstrated the occurrence
of protein glutathionylation/deglutathionylation in dopaminergic cells and
experimental PD models, but these observations have been restricted to the
mitochondria. In this study, we demonstrated that GRX1 has the ability to
promote both glutathionylation and deglutathionylation in dopaminergic
cells, and this was modulated by the oxidative stress induced by paraquat.
For example, PSSG levels were decreased by paraquat exposure and
overexpression of GRX1 not only increased PSSG formation by itself, but
this effect was enhanced by paraquat (see Fig. 3C upper panel and 3D). The
glutathionylating activity of GRX1 under these circumstances might be
ascribed to the increased levels of oxidized GSH (GSSG or GS•) acting as
substrate for GRX1 (Fig. 8A). In other cases, an increase in PSSG was
induced by either paraquat or GRX1 overexpression, and this was reversed
by both paraquat and high GRX1 levels (see Fig. 3C, lower panel), which
could be associated with inactivation or degradation of GRX1 by oxidative
stress. These results support the idea that paraquat-induced alterations in
PSSG are determined by distinct variables, including the susceptibility of
the protein (redox potential and availability of cysteine residues), the redox
environment surrounding the protein, the generation of pro-oxidant
conditions, and possibly the compartmentalization of these events.
GRX1 appears to be expressed at lower levels in the substantia nigra and
striatum compared to other brain areas (3, 7), which suggests that the low
expression levels of this thiol transferase might render dopaminergic cells
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more susceptible to oxidative stress. GRX1 and GRX2 have been suggested
to play a protective role against dopamine toxicity in neuronal cells (16, 17).
Downregulation of GRX1 itself has been shown to induce a decrease in
complex I activity, mitochondrial membrane potential, DJ-1 loss (a putative
gene recessively linked to early onset of PD), translocation of DAXX (a
death-associated protein), and cell death (46, 68, 69). Mieyal's research
group recently reported that levodopa (L-DOPA), a dopamine precursor
used in the clinical treatment for PD, directly inactivates GRX1 and induces
dopaminergic cell death by activation of the apoptosis signaling kinase 1
(ASK-1) (66, 67). On the other hand, downregulation of mitochondrial
GRX2 has been shown to disrupt iron–sulfur center biogenesis and complex
I activity in dopaminergic cells, while its overexpression protects against
MPTP-induced toxicity (45, 48). In mouse embryonic fibroblasts, lack of
GRX1 is associated with increased sensitivity to paraquat toxicity (36).
However, the protein target(s) subject to either
glutathionylation/deglutathionylation that might mediate the protective
effects of GRXs in dopaminergic cells have not been elucidated. It is
important to notice that overexpression of GRX1 only partially protects
dopaminergic cells. This is explained by the observation that paraquat
induced a decrease in the levels of overexpressed GRX1. In addition, GRX1
requires GSH/GSSG for its glutathionylating/deglutathionylating activity,
and paraquat toxicity is associated to GSH depletion by its oxidation to
GSSG and possibly, by GSSG extrusion outside of the cell, both of which
might alter GRX1 activity (Fig. 8A and 8B).
Paraquat triggers a dose-dependent decrease in cell viability and
mitochondrial activity (Figs. 1B, 2B, and 2C). Overexpression or knock-
down of GRX1 regulate PQ-induced cell death irrespective to the
concentration used. However, alterations in PSSG levels presented distinct
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patterns. In some cases, paraquat induced a dose-dependent decrease in
PSSG residues (Fig. 3A, protein band a). In other cases (Fig. 3A, protein
bands c, d and f), lower concentrations of paraquat (0.1 and 0.2 mM)
induced an initial increase in PSSG residues that were deglutathionylated in
response to higher paraquat doses (0.5 and 1 mM). This biphasic behavior
might be explained by the presence of distinct protein targets with distinct
redox potentials in WB bands or by the distinct susceptibility (distinct pKa
values) of different cysteine residues within protein targets subject to
glutathionylation/deglutathionylation or hyperoxidation.
GRX1 has been shown to protect against oxidative stress by regulation of
pro-apoptotic signaling proteins such as the ASK-1 (77). Although distinct
proteins both in the cytosolic and mitochondrial compartments have been
reported to be the target for glutathionylation (39, 55), very few
glutathionylated proteins have been identified in dopaminergic cells in
experimental PD and these have been restricted to the mitochondria.
Mitochondrial protein deglutathionylation has been reported in response to
oxidative stress in dopaminergic cells (56), while increased IDPm
glutathionylation was reported in the MPTP mouse model (47). Paraquat is
known to induce oxidative stress in both mitochondria and cytosolic
compartments (10, 13, 64), thus, we wanted to identify novel targets of
protein glutathionylation using a human dopaminergic cell line as a robust
experimental model for protein analysis by mass spectrometry. We were
able to identify two new proteins, which to our knowledge, have not been
reported previously to be subject to redox modifications. These two protein
targets, FLI-I and REPS2, were degraded upon paraquat treatment and this
was paralleled by executioner caspase activation. GRX1 overexpression was
able to significantly reduce the degradation of FLI-I and REPS2, and this
was associated with reversal in paraquat-induced
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glutathionylation/deglutathionylation of these enzymes, suggesting that
under oxidative conditions, GRX1 might exert a protective effect against the
degradation of proteins by modulation of
glutathionylation/deglutathionylation residues. For example, it has been
proposed that PSSG prevents critical cysteine residues from overoxidation
(55). Our next step would be to evaluate if
glutathionylation/deglutathionylation of proteins such as FLI-I and REPS2
leads to their degradation by cysteine hyperoxidation.
Actin is a well-known substrate of glutathionylation. Previous reports have
demonstrated that actin glutathionylation occurs via spontaneous oxidation
of a cysteinyl residue to a PSOH that readily reacts with GSH (20, 43). Actin
deglutathionylation is mediated by GRX1 and regulates its polymerization
induced by growth factor stimulation (18, 85, 86). FLI-I is a member of the
gelsolin superfamily of proteins, which contains another six members:
villin, adseverin, capG, advillin, supervillin, and gelsolin. In addition to
their respective role in actin filament remodeling, these proteins have some
specific and apparently non-overlapping roles in several cellular processes,
including cell motility, control of apoptosis, and regulation of phagocytosis
(75). Gelsolin-related actin binding proteins contain a triple repeat of a 125–
150 amino acid residue actin-binding subdomain, referred to as S1, S2, or
S3. In most members, including FLI-I, there are two copies of this triple
repeat region, yielding a six-subdomain protein (S1–S6). The FLI-I protein
also contains a N-terminal leucine-rich repeat region involved in protein–
protein interactions. FLI-I is the only member of the gelsolin superfamily
that is essential for mouse development, as disruption of the mouse
homologue fliih gene results in a rapid degeneration of the embryo (4).
Knock-down of FLI-I increases apoptosis induced by cytokine withdrawal,
suggesting that FLI-I is a survival factor (90). Recently, it was demonstrated
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the ability of FLI-I to bind and inhibit pro-inflammatory caspase 1 (51).
Here we demonstrated that FLI-I is downregulated during paraquat-induced
dopaminergic cell death, and this was paralleled by increased executioner
caspase 3 activation, but whether caspases mediate FLI-I downregulation or
FLI-I regulates executioner caspase activation requires further research.
Importantly, downregulation of FLI-I was significantly prevented by its
GRX1-mediated glutathionylation. Another report demonstrated a direct
interaction of nucleoredoxin, a member of the thioredoxin family of protein
oxidoreductases, with FLI-I, but this seemed to be unaffected by oxidative
stress and independent of the two catalytically active cysteine residues (34).
Overexpression of FLI-I did not prevent paraquat-induced toxicity;
however, further studies are required to clearly determine its role in
dopaminergic cell death as both its expression levels and redox status
(glutathionylation) seem to be altered during oxidative stress-induced by
paraquat.
REPS2/POB1 is homologous in sequence and domain structure to REPS1.
The Reps (Related to Eps15) proteins contain a domain homologous to
Eps15, which has been identified in 11 human proteins. REPS2 regulates the
signaling processes by altering the localization of a molecule within the
cell, thus linking signaling and intracellular trafficking. Four isoforms of
REPS2 have been identified. Two short (58 kD) isoforms and two long (78 
kD) ones (6). mRNA and protein analysis demonstrated that REPS2 is
predominantly expressed in the central nervous system as compared to other
tissues (33, 40), being particularly enriched in neuronal populations (33,
49). REPS2 has been shown to regulate glutamate receptor endocytosis (33),
but no further studies have addressed its role in neuronal function. REPS2
also regulates cell death pathways. In cancer cell lines, increased expression
of REPS2 is associated with increased apoptosis (59, 76, 91). Similar to
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FLI-I, paraquat-induced toxicity was associated with downregulation of
REPS2, which was significantly reduced by GRX1 overexpression. More
extensive studies are required to identify the specific cysteines in both FLI-I
and REPS2 that are subject to protein oxidation, as well as the exact
mechanisms by which these cellular substrates regulate paraquat-induced
dopaminergic cell death.
In summary, we have demonstrated for the first time, the protective role of
GRX1 and protein glutathionylation against dopaminergic cell death in the
experimental PD models of paraquat and 6-OHDA. Furthermore, we
demonstrate that the protective effect of GRX1 might be ascribed to
alterations in glutathionylation/deglutathionylation of cellular protein
targets, which could potentially protect them from hyperoxidation and/or
degradation during cell death. Finally, we have identified novel molecular
targets of protein glutathionylation, including FLI-I and REPS2; and for the
case of REPS2, we have demonstrated its protective effect against
dopaminergic cell death induced by experimental PD.
Materials and Methods
Cell culture and treatments
Human dopaminergic neuroblastoma cells (SK-N-SH) were obtained from
the American Type Culture Collection (ATCC; Manassas, VA). Cells were
cultured in DMEM/F12 medium containing 10% fetal bovine serum, 100
units/ml penicillin-streptomycin in a humidified 37°C incubator with 5%
CO2. Cell culture reagents were obtained from Thermo Scientific/Hyclone
(Logan, UT) or Invitrogen/GIBCO (Carlsbad, CA). Cells were treated with
paraquat (1,1′-dimethyl-4,4′-bipyridinium dichloride), 6-hydroxydopamine
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hydrochloride (6-OHDA), 1-methyl-4-phenylpyridinium iodide (MPP+),
and rotenone (SIGMA-Aldrich, St. Louis, MO) to induce cell death. 6-
OHDA was prepared in water containing ascorbic acid (0.02%) to prevent its
oxidation.
Plasmids, stable and transient transfections
pCR3.1 vector and pCR3.1 vector expressing human GRX1 were kind gifts
of Dr. Marjorie F. Lou (University of Nebraska, Lincoln, NE) (89). pEF-
BOS-Myc-tagged FLI-I and pcDNA3.1/Myc-His REPS2/POB1 expression
vectors were kindly provided by Dr. Hiroaki Miki (Laboratory of
Intracellular Signaling, Institute for Protein Research, Osaka University)
(34) and Dr. Luisa Castagnoli (University of Rome Tor Vergata) (83),
respectively. Plasmids were linearized with ScaI (pCR3.1) and PvuI
(pcDNA3.1) restriction enzymes and transfected into SK-N-SH cells using
FuGENE HD reagent (Promega, Madison, WI). Stable cells overexpressing
REPS2 were selected in complete medium containing 0.3 mg/ml geneticin.
Transient expression of Myc-tagged FLI-I was performed with FuGENE
(4.5 FuGENE: 1 DNA).
Knockdown of GRX1
Knockdown experiments were designed according to previous studies (65).
Cells were stably transduced with mission short hairpin small interference
RNA (shRNA) lentiviral particles (Sigma-Aldrich). Cells were infected with
the lentiviral pLKO.1 shRNA vectors (Sigma Mission shRNA library)
TRCN0000036224 / NM_002064.1-229s1c1, named shRNA-4, Sequence:
CCGGCGAGTCTTTATTGGTAAAGATCTCGA
GATCTTTACCAATAAAGACTCGTTTTTG;
TRCN0000036225/NM_002064.1-111s1c1, named shRNA-5, Sequence:
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CCGG CCTCAGTCAATTGCCCATCAACTCGAGTTGATGGGC
AATTGACTGAGGTTTTTG; TRCN0000036226/NM_002064.1-260s1c1,
named shRNA-6, Sequence: CCGGGATGCAG
TGATCTAGTCTCTTCTCGAGAAGAGACTAGATCACT
GCATCTTTTTG; TRCN0000036227 / NM_002064.1-172s1c1, named
shRNA-7, Sequence: CCGGCACACTAACGAGAT
TCAAGATCTCGAGATCTTGAATCTCGTTAGTGTGTTT TTG; and
TRCN0000036228 / NM_002064.1-242s1c1, named shRNA-8, Sequence:
CCGGGTAAAGATTGTATAGGCGG
ATCTCGAGATCCGCCTATACAATCTTTACTTTTTG; and selected in
medium containing 3 μg/ml puromycin after 48 h post-transfection. As
control, we used a non-target shRNA pLKO.1 (SHC002, Sequence:
CCGGCAACAAGATGAAGAGC
ACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT) coding for the
puromycin resistance gene and containing a sequence that should not target
any known human gene (scramble), but will engage with the RNA-induced
silencing complex (RISC). All lentiviruses were packaged in HEK293T cells
according to established protocols (8). Briefly, HEK293T cells were
transiently transfected with pMD2G, psPAX2, and transfer vector
containing the shRNA sequence using Lipofectamine 2000. Supernatant was
collected 48 h post-transfection and concentrated by centrifugation at 50,000
g for 2 h. The pellets were resuspended in PBS and used for infection. Only
shRNA-4 and shRNA-8 decreased GRX1 basal and overexpression levels
(data not shown).
Recombinant adenoviral vectors
The replication-deficient recombinant adenovirus (E1 deletion) Ad5CMV-
GRX1 containing the transgene for human GRX1 under the control of the
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CMV promoter was kindly provided by Dr. J.J. Mieyal of Case Western
Reserve University, Cleveland, OH (72). Control adenoviruses containing
only the cytomegalovirus promoter (AdEmpty) or the green fluorescent
protein gene as a reporter (AdGFP) were used as controls. Adenoviruses
were amplified in HEK293T cells according to established protocols (8).
HEK293T cells were infected and then harvested when cytopathic effect was
observed (CPE). Pellet and supernatant were harvested, three rounds of
freeze/thaw were performed to release viral particles, and debris was
removed by centrifugation. Viruses in the supernatant were titered using a
modification of the end-point dilution assay. SK-N-SH cells were infected
with adenoviral vectors at a multiplicity of infection (MOI) of 0.15–15 and
treated with experimental conditions 24 h post-infection.
Measurement of mitochondrial activity (cytotoxicity assay)
Mitochondrial activity was assessed as a marker of cytotoxicity by
measuring the conversion of the tetrazolium salt, MTT, to formazan. After
treatment, cells were incubated with MTT (0.5 mg/ml, Sigma) at 37°C.
Then, lysis buffer (10% SDS in 0.01 N HCl) was added and samples were
incubated until complete lysis. Absorbance was measured at 570 nm and
results were expressed as % of mitochondrial activity with respect to the
control (untreated) cells.
Analysis of cell viability by FACS
After treatment, floating and attached cells were collected. Loss of cell
viability was determined by propidium iodide uptake (PI, Sigma) as a
marker for plasma membrane integrity loss using flow cytometry (FACS,
Fluorescence Activated Cell Sorting). PI was detected in FL-3 (488 nm
excitation, 695/40 nm emission) or L2-4 (561 nm excitation and 615/25 nm
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emission) in a BD FACScaner (BD Biosciences, San Diego, CA) or
BDFACSort (Cytek-DxP-10 upgrade), and data were analyzed with
CellQuest or FlowJo 7.6.5 software.
Western blotting under reducing and nonreducing conditions
After treatments, cells were collected in RIPA buffer (25 mM Tris.HCl, pH
7.6, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS)
supplemented with Halt Protease Inhibitor (Thermo/Pierce, Rockford, IL).
To normalize protein concentration, protein content from whole cell lysates
was determined via the bicinchoninic acid method (BCA, Thermo/Pierce).
NuPAGE LDS sample buffer (Invitrogen) was added to the samples with
(reducing conditions) or without reducing agent (nonreducing conditions)
and heated for 10 min at 70°C. Samples were separated on NuPAGE 4%–
12% Bis-Tris gels (Invitrogen) with (reducing conditions) or without
antioxidant (nonreducing conditions), and transferred to nitrocellulose
membranes (Whatman/GE Life Sciences, West Grove, PA) using NuPAGE
transfer buffer and a TE70X semi-dry blotter (Hoefer, San Francisco, CA).
Membranes were probed with the appropriate antibodies: anti-GRX1
(Abcam, Cambridge, MA); anti-α-fodrin, anti-cleaved caspase 3 (ASP175)
(Cell Signaling Technology, Danvers, MA), anti-LC3B (SIGMA), anti-
glutathione (anti-PSSG, Virogen,Watertown, MA); anti-GAPDH (Cell
Signaling Technology), anti-β-actin (Sigma), anti-FLI-I (Bethyl
Laboratories, Montgomery, TX), anti-Myc Tag (clone 4A6, EMD/Millipore)
and anti-REPS2 (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C
overnight. Peroxidase conjugated secondary anti-rabbit or anti-mouse
antibodies (1:5000, GE Life Sciences, Abcam or Thermo/Pierce or Cell
Signaling Technology) were used, and bands were detected using ECL
Western blotting substrate (GE Life Sciences or Thermo/Pierce). To identify
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alterations in protein glutathionylation, cells were collected in RIPA buffer
containing >30 mM N-ethylmaleimide (NEM) (Sigma-Aldrich) to
irreversibly block free thiols and minimize further thiol–disulfide exchange,
and samples were analyzed under nonreducing conditions as explained
above. The addition of NEM stabilizes PSSG by preventing the transfer of
GSH from one protein thiol to another. NEM blocks exposed thiols that have
not been glutathionylated and also thiols that become exposed by
denaturation of the protein during sample processing. 10 mM NEM was
supplemented into the blocking buffer after the proteins were transferred to
nitrocellulose membranes. Glutathionylated proteins were visualized using
an anti-glutathionylated (anti-PSSG) antibody, which is raised against GSH
connected by a thioether bond through a linker to a keyhole limpet
hemocyanin.
Immunoprecipitation
Cells were collected and lysed in RIPA buffer. 300–500 μg protein for each
sample were pre-cleared with either Trueblot mouse IgG beads
(eBIOSCIENCE, San Diego, CA), or protein A Dynabeads (Invitrogen)
coupled to normal rabbit or mouse IgG for 1 h at 4°C, and then washed in
buffer containing 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 2 mM EDTA,
and 10% glycerol. Then, immunoprecipiation was performed by incubating
protein samples for 1 h at 4°C with Dynabeads bound to the corresponding
primary antibody (0.2–2 μg per sample) using the Dynal Magnetic Particle
Concentrator (Invitrogen). Proteins were eluted with glycine elution buffer
(100 mM glycine, pH 2.5) for mass spectrometry analysis or NuPAGE LDS
sample buffer with or without (PSSG immunoprecipitation) reducing agent
for Western immunoblot. For immunoprecipitation using the anti-PSSG
antibody, free GSH was initially removed from protein samples with a
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Nanosep 3K centrifugal device (Pall Life Science, Port Washington, NY) at
14000 g for 5 min.
Analysis of glutathionylated proteins using biotinylated GSH ester
This method was modified from previously described protocols (12, 79).
Biotinylated GSH ester (BioGEE) was prepared by mixing equal volumes of
25 mM sulfo-NHS-biotin (Thermo/Pierce) with 25 mM GSH ethyl ester
(Sigma) in 50 mM NaHCO3 at pH 8.5, followed by the addition of 125 mM
NH4HCO3 at pH 8.5. To terminate the reaction, 1.25 M NH4HCO3 was
added to quench the remaining biotinylation reagents at 5-fold molar excess
of the starting sulfo-NHS-biotin concentration. Cells were pre-incubated in
serum-free media with BioGEE (250 μM) for 1 h and then treated with the
corresponding experimental conditions. Then, cells were collected, washed
and lysed in a nondenaturing lysis buffer (TrisHCl 25 mM, pH 7.4, NaCl
150 mM, MgCl2 5 mM, 1% NP-40) containing 10 mM NEM. After
sonication and centrifugation, the samples were analyzed under nonreducing
conditions, and glutathionylated proteins were visualized using
streptavidin–HRP conjugate (Thermo/Pierce).
Mass spectrometry analysis and protein identification
Glutathionylated proteins immunoprecipitated with anti-PSSG antibody
were immediately neutralized with 1 M Tris.HCl (pH 8), and processed for
mass spectrometry. Samples were initially buffer exchanged with 100 mM
ammonium bicarbonate buffer pH 8.0, reduced using DTT and alkylated
using iodoacetamide. Samples were then digested using Trypsin (Roche)
and subsequently dried using Speed Vac concentrators. Peptides were
subjected to LC/MS/MS analysis using reverse phase chromatography mass
spectrometry. The LC/MS/MS analysis was carried out using a Dionex U
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3000 nano LC unit. Sample loading on the monolithic trap column was
conducted using a micro pump. The desalted peptides were eluted and
separated on a C 18 Pep Map column (75 μm I.DX15 cm, 3 μm) applying an
acetonitrile gradient (ACN plus 0.1% formic acid) and introduced into the
mass spectrometer using the nano spray source. The LCQ Fleet mass
spectrometer (Thermo Electron Corporation) operates with the following
parameters: nano spray voltage (2.0 kV), heated capillary temperature 200C,
full scan m/z range 400–2000. The LCQ was operated in data dependant
mode with 4 MS/MS spectra for every full scan, 5 microscan averaged for
full scans and MS/MS scans in CID mode. The acquired spectrum was
searched against human data base (IPI-Human, NCBI) for sequence analysis
using MASCOT data base analysis software.
In vivo mouse model of paraquat toxicity
C57BL/6 mice (8–10 weeks old) (Jackson Labs) were administered two
intraperitoneal injections of 10 mg/kg PQ or PBS every week for 3
consecutive weeks. Animals were analyzed 1 week after the last injection.
Mice were perfused intracardially with 4% paraformaldehyde (PFA) in 0.1
M sodium phosphate buffer (pH 7.4). Brains were removed, post-fixed for
24 h in 4% PFA and cryoprotected with 30% sucrose. Frozen brains were cut
into 30 μm coronal sections using a sliding microtome at −16°C, and stored
in PBS at 4°C until the immunohistochemical procedure. Endogenous
peroxidase activity was inactivated. Sections were blocked with 10% normal
horse serum (GIBCO) and incubated 48 h with rabbit anti-TH antibody
(Calbiochem, EMD/Millipore) anti-REPS2 or anti-PSSG at 4°C. After
rinsing, sections were incubated in secondary Alexa 488-anti-rabbit or
Alexa 633-anti-mouse (Molecular Probes/Invitrogen) for 1 h at RT. Sections
were mounted with VectaShield (Vector Laboratories, Burlingame, CA).
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Images were collected on a LSM 5 Exciter confocal scanning fluorescent
microscope (20×) and Zen 2008 software (Carl Zeiss).
Statistical analysis
All experiment replicas were independent and performed on separate days.
Collected data were analyzed according to statistical criteria by using paired
or unpaired t-test, one-way ANOVA or two-way ANOVA, and the
appropriate parametric or nonparametric normality post-test using a
SIGMA-PLOT/STAT package. A probability value of p<0.05 was
considered as statistically significant. Data were plotted as mean values of
at least three independent experiments±standard error of the mean (SEM)
using the same statistical package for data analysis. Flow cytometry plots
and Western blots presented were representative of at least three
independent experiments. Confocal image analysis and densitometry
analysis of immunoblots were performed using ImageJ (NIH) v3.91
software (http://rsb.info.nih.gov/ij). Corrected total cell fluorescence
(CTCF) was obtained with the next formula CTCF=Integrated Density –
(Area of selected cell X Mean fluorescence of background readings).
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FIG. 1.
Stable overexpression of GRX1 protects against dopaminergic cell death
induced by paraquat and 6-OHDA. Human dopaminergic SK-N-SH cells were
stably transfected with empty pCR3.1 vector and pCR3.1 vector encoding human
GRX1 (A). In B–D, the effect of GRX1 overexpression against cell death induced by
a 48 h treatment with paraquat (0.5 mM in C) or 6-OHDA (50 μM) (D) was analyzed
by determination of mitochondrial activity (B) and cell viability (C and D).
Mitochondrial activity (B) was assessed by measuring the conversion of the
tetrazolium salt, MTT. Loss of cell viability or plasma membrane integrity is reflected
by the increase in the number of cells with increased PI fluorescence (plots and bar
graphs in C and D). Data in bar graphs represent % of viable cells from paraquat (C)
and 6-OHDA (D) treated cells and are means±SEM of four independent
experiments. *p<0.05, significant difference between GRX1 and pCR3.1 values.
Contour plots and Western blots are representative of 2–4 independent experiments.
Numbers in A represent the densitometry analysis with respect to SK-N-SH cells
normalized to β-actin.
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FIG. 2.
Adenovirus-mediated overexpression of GRX1 and shRNA knock-down
regulate dopaminergic cell death induced by paraquat. Overexpression of
GRX1 by recombinant adenovirus Ad5CMV-GRX1 (1.5 MOI) and GRX1 knock-down
with shRNA lentiviral particles were determined by Western blot (A). The effect of
GRX1 overexpression (C and D) and knock-down (B) on the loss of mitochondrial
activity (B and D) and cell death (C) induced by paraquat was determined as in
Figure 1. In E, the effect of paraquat (48 h treatment) on the overexpression of GRX1
induced by Ad5CMV-GRX1 (1.5 MOI) was evaluated. Cleavage of α-fodrin
(apoptotic marker) and accumulation of LC3-II (autophagy marker) induced by
paraquat were also determined by Western blot in whole cell lysates (F). Control
adenovirus contained only the cytomegalovirus promoter (AdEmpty) and/or the green
fluorescent protein gene as a reporter (AdGFP). Data in graphs represent means
±SEM of four independent experiments. *p<0.05, shRNA4 and 8 vs Scramble (C), or
GRX1 vs. Empty values (D). Plots in (C) represent 0.5 mM PQ treatments. Contour
plots and Western blots are representative of 3–4 independent experiments.
Numbers in blots (italics) represent the densitometry analyses with respect to
Scramble (A), Ad-GRX1 (E), and Ad-Empty samples (F) normalized to β-actin or
GAPDH.
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FIG. 3.
Paraquat-induced alterations in glutathionylated proteins. Whole cell lysates of
cells treated with or without paraquat for 48 h were isolated and analyzed under
reducing (-NEM/+DTT) and nonreducing (+NEM/-DTT) conditions. In A and B,
protein glutathionylation was assessed using anti-PSSG antibody in samples
isolated in the presence or absence of >30 mM NEM. In C, overexpression of GRX1
was induced via adenoviral transduction (1.5 MOI) as described in Figure 2. C
represents a composite of two independent Western blot with their corresponding
loading controls. In D, protein glutathionylation was assessed as previously
described in cells labeled with BioGEE (250 μM) 1 h prior to experimental
treatments, and glutathionylated proteins were visualized using streptavidin-HRP
conjugate. Blots were probed with β-actin to determine equal loading. Blots are
representative of at least 3 independent experiments. Numbers in blots (italics)
represent the densitometry analyses with respect to control (A, table), and Ad-Empty
samples (C and D) normalized to β-actin.
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FIG. 4.
Paraquat toxicity is associated with downregulation of FLI-I and REPS2. (A)
Glutathionylated proteins immunoprecipitated with anti-PSSG antibody were
processed for mass spectrometry. Samples were digested with trypsin and peptides
were subjected to LC/MS/MS analysis using reverse phase chromatography mass
spectrometry. Two of the acquired spectrum of peptides identified by mass
spectrometry analysis corresponded to FLI-I (ACSAIHAVNLR) and REPS2
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SAGSAEQVAPAAAQGGSSRTNCIGKPIGTTSSGHCVV), identified using a human
data base (IPI-Human, NCBI). (See Supplementary Fig. S1 for a magnification of the
MS spectra). Alterations in the levels of FLI-I, REPS2 and cleaved caspase 3
induced by paraquat were assessed in wild-type (B) and stable SK-N-SH
overexpressing Myc-His REPS2 (D). In (C) and (D), REPS2 protein levels were
visualized in stable Myc-His REPS2 overexpressing clones (clone 2 was used in D)
using anti-myc-tag (upper panel) or anti-REPS2 (K-18) (lower panel) antibody. a–c
labels in C and D (including the table) represent possible isoforms or degradation
products of REPS2. Blots were reprobed with β-actin to corroborate equal loading
and are representative of at least 3 independent experiments. Table corresponds to
the densitometry analysis of protein bands in D. Numbers (italics) in (B) and (D)
represent the densitometry analyses with respect to control samples (D, table)
normalized to β-actin.
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FIG. 5.
GRX1 regulates protein expression levels and glutathionylation of FLI-I and
REPS2. In (A) and (B), overexpression of GRX1 (Ad-GRX1) reduced paraquat-
induced FLI-I and REPS2 downregulation (broken line rectangles). SK-N-SH (A and
C) and cells stably expressing Myc/His REPS2 (B and D) were infected with Ad-
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Empty or Ad-GRX1 (1.5 MOI) for 24 h and subsequently treated with paraquat (0.2 
mM in A, C upper panel, and D) for 48 h. Samples were collected under
nonreducing conditions (+NEM/-DTT). In C (upper panel) and D, FLI-I and REPS2
were immunoprecipitated with anti-FLI-I or anti-MycTag antibodies respectively, and
then, PSSG were visualized using anti-PSSG antibody. Blot in (C, upper panel) was
reprobed with anti-FLI-I to corroborate equal levels of immunoprecipitated proteins.
In (C, lower panel), glutathionylated proteins were immunoprecipiated with anti-
PSSG antibody and FLI-I levels were visualized using the corresponding antibody.
As controls, samples were pre-cleared with Dynabeads coupled with normal mouse
IgG. Normal mouse IgG did not pull down FLI-I. Blots are representative of at least 3
independent experiments. Numbers in blots (italics) represent the densitometry
analyses with respect to Ad-Empty samples [0.15 MOI, upper numbers; and 1.5 MOI
lower numbers in (A)], normalized to the corresponding loading/input control.
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FIG. 6.
Paraquat-induced dopaminergic cell death is significantly reduced by
REPS2/POB1 overexpression. (A) SK-N-SH cells overexpressing empty
pcDNA3.1 or Myc-His REPS2 were treated with paraquat for 48 h. Cell death was
determined by the loss of plasma membrane integrity (PI uptake) and cell shrinkage
as a marker of apoptosis. % of dead cells in A (bar graph) reflects the number of
cells with increased PI fluorescence using two distinct clones overexpressing Myc-
His REPS2 (See Fig. 4C). In B, paraquat-induced cleavage/activation of caspase 3
in both pcDNA3.1 and REPS2 overexpressing cells was evaluated as explained in
Figure 2. In C and D, cells were transiently transfected with Myc-tagged FLI-I for 24 h
prior paraquat treatment. Expression levels of FLI-I were corroborated by Western
blot (C) and the effect of FLI-I overexpression on paraquat-induced dopaminergic
cell death was determined as explained in A. Data in A (bar graphs) and D are
means±SEM of four independent experiments. *p<0.05, significant difference
between the corresponding REPS2 and pcDNA3.1 values. Contour plots and
western blots are representative of 3–4 independent experiments. Numbers in B
(italics) represent the densitometry analyses of cleaved caspase 3 with respect to
pcDNA normalized to β-actin.
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FIG. 7.
Alterations in PSSG and REPS2 in the substantia nigra of mice treated with
paraquat. C57BL/6 mice (8–10 weeks old) were administered two intraperitoneal
injections of 10 mg/kg PQ or PBS every week for 3 consecutive weeks. Animals
were analyzed 1 week after the last injection and coronal sections of the substantia
nigra were stained with anti-TH (A and B) and anti-PSSG (A) or anti-REPS2 (B)
antibody. Sections were incubated in secondary Alexa 488-anti-rabbit (TH) and
Alexa 633-anti-mouse (PSSG and REPS2). Sections were mounted with
VectaShield and images were collected on a LSM 5 Exciter confocal scanning
fluorescent microscope (20 ×) and Zen 2008 software (Carl Zeiss). Fluorescence
intensity analysis was performed using ImageJ (NIH) software. Corrected total cell
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fluorescence (CTCF) was obtained and expressed as Arbitrary Fluorescence
Intensity Units (A.U.).
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FIG. 8.
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Proposed mechanism by which paraquat-induced oxidative stress and
GRX1 might regulate protein glutathionylation and deglutathionylation
distinctively. Protein glutathionylation has been demonstrated to occur by a variety
of mechanisms, reviewed in (55, 88). (A) PSSG formation might occur by thiol
exchange reactions between protein cysteines and GSSG, but this mechanism
requires unusually high redox potential. Interestingly, under oxidizing conditions (low
GSH/GSSG ratio) GRX1 can use GSSG to promote PSSG formation. Paraquat-
induced↑RS might enhance GRX1-mediated glutathionylation by increasing the
GSSG pool (dotted line). (B) Under reducing conditions, GRX1 utilizes the reducing
power of GSH to catalyze protein deglutathionylation. Paraquat-induced reactive
species (↑ RS) formation might prevent GRX1-mediated deglutathionylation by
depletion of intracellular GSH content (broken lines). On the other hand, two (H2O2,
•ONOO-) or one-electron (•O2-) cysteine oxidation by RS leads to the formation of
reactive intermediates including cysteine sulfenic acids (PSOH) (C) and protein thiyl
radicals (PS•) (D), respectively, which can participate in disulfide bond formation
with GSH leading to PSSG formation (E). In addition, GS• generation by oxidative
stress has been shown to lead to PSSG formation catalyzed by GRXs (not depicted
here). This is another potential mechanism by which GRX1 overexpression might
increase protein glutathionylation upon paraquat exposure. Paraquat-induced RS
formation and GSH depletion mediated by increased activation of glutathione
peroxidase (GPX) (broken lines) might enhance cysteine oxidation and also
prevent/reverse cysteine glutathionylation leading to their irreversible oxidation (G).
Thus, glutathionylation/deglutathionylation depends on the spacial localization of the
targeted protein, surrounding redox environment, the nature of the RS involved and
expression levels of GRXs (F).
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